The Art Of Software Pharmaphorum podcast

pharmaphorum Podcast

1
IRA updates and making sense of the chaos in Washington, with Alice Valder Curran 38:29

8 dagen geleden38:29

38:29

Last year, Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert in Washington, D.C. joined host Jonah Comstock on the pharmaphorum podcast to talk about the intended and unintended consequences of the drug pricing negotiation provisions in the Inflation Reduction Act. On today’s episode, Curran joins us once again for an update on the IRA, looking at the second batch of drugs announced in January, recent messaging from the Centers for Medicare and Medicaid Services and what it might communicate about their thinking, and more analysis of IRA’s consequences, including a recent study on the impact of the IRA on early stage investment. She also talks about the possibility that, because of perverse incentives for pharmacy benefit managers, patient access to medications negotiated under the IRA could actually get worse. And she looks ahead to the third round of negotiations, which will see Part D drugs, including Keytruda, become eligible. While the IRA was the main focus of discussion, Curran and Comstock discuss a lot more about the current chaotic environment in DC, including the potential impact of layoffs on the functioning of agencies like CMS and FDA, the outlook for the possibility of IRA reform under the Trump administration, and the recent dispatch from Secretary of Health and Human Services Robert F. Kennedy indicating a change in policy around notice and comment rulemaking. Things are happening fast in the United States government and the ripples could have big effects for the pharma industry. Tune in for the low-down from an expert insider.…

pharmaphorum Podcast

1
GenAI and the revolution of drug development 11:05

22 dagen geleden11:05

11:05

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life sciences sector can speed up the process, wiping months or even years off that average. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development. Though it might seem an obvious path, not all life sciences companies are jumping on the bandwagon to adopt GenAI. Instead, many are taking a wait-and-see approach, staying put until the course forward is clearer to incorporate the technology. You can listen to episode 169a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Patient-focused manufacturing models for personalised therapies 22:44

28 dagen geleden22:44

22:44

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs into medicines developed rapidly and robustly to - ultimately - end cancer. Taking learnings from the monoclonal antibody field to come up with a fit-for-purpose solution, Bock discusses his work in the joint venture between the MD Anderson Cancer Center and biopharmaceutical manufacturer Resilience – combining industrial manufacturing and development capabilities with the work of an academic medical centre. CTMC’s is a “patient adjacent” manufacturing model – crucial when it comes to developing personalised therapies (especially when dealing with living cells), and Bock explains how patient-centric approaches streamline manufacturing processes, improve efficacy, and allow for that personalised treatment approach, particularly when the supply chain is local. You can listen to episode 168a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
On specialty pharmacies and prior authorisations 18:13

30 dagen geleden18:13

18:13

Prior authorisations (or PAs) have long put a burden on pharmacy and medical practices, ultimately causing delays for patients. In a new podcast, web editor Nicole Raleigh speaks with Andrew Burns, chief revenue officer at DrFirst, about the ramifications of delayed patient care when it comes to specialty medications. Exploring the current PA landscape, the conversation touches upon specialty pharmacy services and medications, helping to treat rare and complex medical conditions like cancer, rheumatoid arthritis, and multiple sclerosis. Mentioned also are the place of advanced AI and automation technologies, and patient-supportive education, in such services. It is, after all, about better health outcomes for patients. You can listen to episode 167a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Paediatric rare diseases: Children are not small adults 16:56

5 weeks geleden16:56

16:56

Around 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients dying before the age of five, the need for different treatment methods for children is clear. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Children’s National Medical Center. The conversation touches upon incentivisation for manufacturers to develop drugs to treat rare diseases, addressing age-appropriate formulations and recognising the metabolic differences between children and adults, and looks also at clinical trial design. It’s clear that the time for action is now, and serving the paediatric patient population through every stage of the drug delivery process will lead to better adherence and more effective disease management. You can listen to episode 166a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Defining, building, and implementing in the next wave of biopharma R&D 25:27

6 weeks geleden25:27

25:27

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma breakthroughs. PharmaLex’s Dr Christian Schneider, VP & Chief Medical Officer, Clinical Development Services, together with Dr Christelle Boileau, Director of Regulatory Development Strategy and IPD solution lead at PharmaLex, which is part of Cencora, explore the many challenges faced across the clinical trial landscape when it comes to new therapies, including ATMP development. From preclinical to market access and regulatory considerations, Dr Boileau warns that development is not a linear process, and for both an early-as-possible strategy is paramount. Comparing classical paradigms with the new, traditional endpoints need to be reassessed – for example, when defining dosage – says Dr Schneider. You can listen to episode 165a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Insights from JP Morgan Healthcare 2025: Key trends shaping the pharma industry 1:04:49

7 weeks geleden1:04:49

1:04:49

The JP Morgan Healthcare Conference remains one of the most influential events for the life sciences sector, setting the stage for major deal-making, investment trends, and strategic shifts that will define the year ahead. Keen to capture all the key trends and talking points from this year’s event, pharmaphorum editor-in-chief, Jonah Comstock, hit the ground running in Philadelphia, live blogging key sessions and interviewing experts to find out what industry insiders foresee for 2025. In this special extended episode of the pharmaphorum podcast, Jonah sits down with Deep Dive editor, Eloise McLennan, to break down the key themes and takeaways from this year’s event. From the impact of the new Trump Administration on research and development to advancements in brain health, PBM reform, and the evolving role of GenAI in clinical trials, they explore the discussions and developments set to shape pharma’s trajectory in 2025 and beyond. Plus, hear exclusive interviews from experts, including: Catherine Owen Adams from Acadia Pharmaceuticals on trends and innovations in brain health NKarta’s Paul Hastings discusses natural killer cells and developments in cell and gene therapies Evidation’s Phil Johnson on the role of real world data in drug development Grove AI’s Tran Le and Sohit Gatiganti on the immense potential of AI in audio for clinical trials You can listen to this episode, as well as previous episodes of the pharmaphorum podcast , in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
‘Show me the molecule’ – On synthetic biology and cutting through AI hype 15:01

7 weeks geleden15:01

15:01

Therapeutic antibodies are a vital weapon in combating diseases such as cancer, but developing these treatments through conventional methods is slow and unreliable. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug discovery company pioneering the discovery of next-generation therapeutic antibodies in order to solve this predicament. Dr Field speaks to how can industry cut through the hype that surrounds AI and optimally assess the technical underpinnings of an AI proposition in medicine. He describes how LabGenius overcomes the so-called “cognition barrier” by using mathematical models to understand how molecules will respond to disease, and then designs novel therapeutics with the right collection of properties. You can listen to episode 164a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Simulated clinical trial populations and AI scalability 29:03

8 weeks geleden29:03

29:03

AI might still be in the modish buzzword stage, but discussions exploring the potential for its scaling within life sciences are critical. In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores the potential for scaling advanced technologies in the biopharmaceutical industry. From digital twins and insilico modelling and the potential to reduce experimentation in human populations with simulated populations and differently designed trials, to document authoring and automation for time-saving purposes – the conversation on leveraging AI turns also to the global regulatory landscape. You can listen to episode 163a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Rare disease and the women's health gap 15:43

9 weeks geleden15:43

15:43

For women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every one man, and the women’s health gap more generally. Schranz explains the importance of developing a more individualised approach to management and treatment of PBC for each patient and discusses Ipsen’s PBC therapy Iqirvo (elafibranor). You can listen to episode 162a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
From science fiction to reality: AI in drug development 21:32

10 weeks geleden21:32

21:32

With about 92% of new drugs failing in human clinical trials, pharma companies face tremendous financial losses and, more importantly, development and delivery of potentially life-saving treatments are woefully delayed. In today’s pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about how AI could revolutionise preclinical research and accelerate the development of potentially life-saving drugs, safely. Exploring the notion of 3D organ modelling, combining AI and ‘advanced’ biology such as organ-on-chip, and delving into his research passion of the rare diseases space, including FragileX, Bentwich explains that there might be a long road left to travel, but with the acceleration that has taken place with such technology over the past few years, the horizon of success might not be too far off in the distance. No longer science fiction, we are living in the realm of tangible results and possibilities with AI. You can listen to episode 161a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes , Spotify , Amazon Music , Podbean , and pretty much wherever you get your other podcasts!…

pharmaphorum Podcast

1
Precision medicine, NGS, and the quantum leap in biomarkers 23:30

14 weeks geleden23:30

23:30

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers. Quagliata discusses Thermo Fisher’s ongoing collaboration with EVERSANA, pharmaphorum’s parent company, and that collaboration’s investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company’s value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions. That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies’ – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.…

pharmaphorum Podcast

1
Seeking effective, safe treatment for all with precision dosing 31:14

15 weeks geleden31:14

31:14

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options. Creating new medicines by enhancing protein function, Richon is driven by the desire to bring drugs to these patients. She and Comstock discuss protein inhibition in comparison to protein enhancement, based on the idea that many diseases are caused by too little of a certain protein – for instance, a new wave in small molecule drug discovery is those that bind to the protein of interest, but also to another protein that modifies the protein of interest, also known as induced proximity. They explore the possibilities of PROTAC targeted protein degrader technology, Richon talking through the example of cystic fibrosis and the role of proteins in longevity there – as well as the future possibilities.…

pharmaphorum Podcast

1
Seeking effective, safe treatment for all with precision dosing 16:48

16 weeks geleden16:48

16:48

Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that recognises biological individuality – especially when it comes to paediatric care. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Sharmeen Roy, chief scientist at DoseMe, for a conversation on precision medicine tools and how pharmacokinetic (or PK) and pharmacodynamic (or PD) characteristics are a – long overdue – trend in pharma at the moment, from lead identification right up to final-stage clinical trials. Advancements in technology a key driver to this end, Dr Roy explains why such tools should be used to promote precision patient care, end to end.…

pharmaphorum Podcast

1
CAR-T therapies: Faster, better, cheaper 17:56

17 weeks geleden17:56

17:56

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics. Working in the in vivo cell therapy space, Johnson discusses the injection of a manufactured vector into a patient to create the CAR-T cells directly inside the body of the patient, without the need for chemotherapy treatment beforehand – hence such hope for in vivo cell therapy’s potential. Targeting both T-cells and NK-cells, Johnson notes that this is a distinguishing factor of the work Interius does. On the CAR-T space generally, Comstock and Johnson explore its evolution and how these products can be made faster, better, and cheaper – including the democratisation of these therapies, and the accessibility gains this means for patients.…

Podcasts die het beluisteren waard zijn

1
Curated Questions: Conversations Celebrating the Power of Questions!

pharmaphorum Podcast « »
The art of software